122 related articles for article (PubMed ID: 23824105)
1. [Late and prolonged pseudoprogression in serial posttreatment MRI due to use of new chemotherapy concepts to treat malignant glioblastoma].
Ganslandt O
Strahlenther Onkol; 2013 Aug; 189(8):706-7. PubMed ID: 23824105
[No Abstract] [Full Text] [Related]
2. Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
Stuplich M; Hadizadeh DR; Kuchelmeister K; Scorzin J; Filss C; Langen KJ; Schäfer N; Mack F; Schüller H; Simon M; Glas M; Pietsch T; Urbach H; Herrlinger U
J Clin Oncol; 2012 Jul; 30(21):e180-3. PubMed ID: 22689800
[No Abstract] [Full Text] [Related]
3. Nothing ventured, nothing gained: Treatment of glioblastoma multiforme in the elderly.
Shaw EG
J Clin Oncol; 2004 May; 22(9):1540-1. PubMed ID: 15051758
[No Abstract] [Full Text] [Related]
4. Bevacizumab and recurrent malignant gliomas: a European perspective.
Wick W; Weller M; van den Bent M; Stupp R
J Clin Oncol; 2010 Apr; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801
[No Abstract] [Full Text] [Related]
5. Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
Kilickap S; Oztoprak I; Yucel B
Acta Oncol; 2012 Apr; 51(4):544-6. PubMed ID: 22201408
[No Abstract] [Full Text] [Related]
6. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab.
Gerstner ER; Frosch MP; Batchelor TT
J Clin Oncol; 2010 Feb; 28(6):e91-3. PubMed ID: 19933906
[No Abstract] [Full Text] [Related]
7. Chemotherapy for high-grade gliomas.
Galanis E; Buckner J
Br J Cancer; 2000 Apr; 82(8):1371-80. PubMed ID: 10780513
[No Abstract] [Full Text] [Related]
8. Fewer dollars, more sense.
Garfield DH; Hercbergs A
J Clin Oncol; 2008 Nov; 26(32):5304-5; author reply 5305. PubMed ID: 18854564
[No Abstract] [Full Text] [Related]
9. Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?
Rieger J; Bähr O; Ronellenfitsch MW; Steinbach J; Hattingen E
J Clin Oncol; 2010 Sep; 28(27):e477; author reply e478. PubMed ID: 20585096
[No Abstract] [Full Text] [Related]
10. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
[TBL] [Abstract][Full Text] [Related]
11. Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.
Fellah S; Girard N; Chinot O; Cozzone PJ; Callot V
J Clin Oncol; 2011 Apr; 29(11):e308-11. PubMed ID: 21263101
[No Abstract] [Full Text] [Related]
12. Pseudoprogression and treatment effect.
Jahangiri A; Aghi MK
Neurosurg Clin N Am; 2012 Apr; 23(2):277-87, viii-ix. PubMed ID: 22440871
[TBL] [Abstract][Full Text] [Related]
13. Leptomeningeal enhancement on preoperative brain MRI in patients with glioblastoma and its clinical impact.
Kim H; Lim DH; Kim TG; Lee JI; Nam DH; Seol HJ; Kong DS; Choi JW; Suh YL; Kim ST
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e366-e373. PubMed ID: 29473335
[TBL] [Abstract][Full Text] [Related]
14. [HIT-GBM: multicenter study of treatment of children with malignant glioma].
Wolff JE; Boos J; Kühl J
Klin Padiatr; 1996; 208(4):193-6. PubMed ID: 8926684
[TBL] [Abstract][Full Text] [Related]
15. Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme.
Márquez-Rivas J; Ramirez G; Ollero-Ortiz A; Giménez-Pando J; Emmerich J; Quiroga-Cantero E; Rivas E; Gómez-González E
J Pediatr Hematol Oncol; 2010 Jul; 32(5):e202-6. PubMed ID: 20523247
[TBL] [Abstract][Full Text] [Related]
16. Apatinib treatment for symptomatic pseudoprogression after standard treatment for glioblastoma multiforme: a case report.
Wang Z; Du F; Sun Y; Guo Y; Song B; Wang Y; Shi X; Jiang W
Ann Palliat Med; 2019 Nov; 8(5):752-757. PubMed ID: 31865735
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy of primary brain tumors.
Levin VA
Neurol Clin; 1985 Nov; 3(4):855-66. PubMed ID: 3001491
[TBL] [Abstract][Full Text] [Related]
18. New treatments for malignant gliomas: careful evaluation and cautious optimism required.
Gilbert MR
Ann Intern Med; 2006 Mar; 144(5):371-3. PubMed ID: 16520480
[No Abstract] [Full Text] [Related]
19. Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients.
Gaviani P; Salmaggi A; Silvani A
J Neurooncol; 2011 Sep; 104(2):617-8. PubMed ID: 21229293
[No Abstract] [Full Text] [Related]
20. WINDOW consortium: A path towards increased therapy efficacy against glioblastoma.
Abdul KU; Houweling M; Svensson F; Narayan RS; Cornelissen FMG; Küçükosmanoglu A; Metzakopian E; Watts C; Bailey D; Wurdinger T; Westerman BA
Drug Resist Updat; 2018 Sep; 40():17-24. PubMed ID: 30439622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
